2 results match your criteria: "Hospital Santa Creu i Sant Pau; Universitat Autònoma de Barcelona (UAB)[Affiliation]"
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.
Eur J Gastroenterol Hepatol
January 2015
aCIBER on Liver and Digestive Diseases (CIBERehd), Hospital Vall d'Hebron bHospital del Mar, IMIM, Universitat Autònoma de Barcelona cHospital de la Santa Creu i Sant Pau dHospital Clínic, Barcelona eCIBERehd H. La Fe, Hospital General Universitario de Castellón, Castellón fHospital Son Espases, Palma de Mallorca gCIBERehd, Hospital Universitari Germans Trias i Pujol, Badalona hCIBERehd, Hospital Carlos III iHospital Universitario 12 de Octubre jHospital Puerta del Hierro kFundación Jiménez Díaz lCIBERehd, Hospital Universitario La Princesa, Madrid mHospital de Cruces, Bizkaia nHospital Virgen Macarena oCIBERehd, Hospital Universitario de Valme, Sevilla pHospital Central de Asturias, Oviedo qHospital Universitario Fundación Alcorcón, Alcorcón rHospital Universitario de La Coruña, A Coruña sHospital Universitario Donostia, Donostia tCIBERehd, Hospital Universitario y Politécnico La Fe uHospital General Universitario de Valencia, Valencia vCIBERehd, Hospital Virgen de la Victoria, Málaga wHospital Universitario San Cecilio, Granada, Spain.
Objectives: The aim of this study was to evaluate the efficacy and safety of entecavir monotherapy in nucleos(t)ide-naive chronic hepatitis B patients and to analyse the influence of the comorbidity burden on therapy outcome.
Methods: We retrospectively analysed data from 237 nucleos(t)ide-naive chronic hepatitis B white patients treated with entecavir (0.5 mg/day) at 23 Spanish centres.
Exhaled nitric oxide fraction as an add-on to ACQ-7 for not well controlled asthma detection.
PLoS One
August 2014
Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona Respiratory Network (BRN), Barcelona, Spain.
Background: The measurement of fractional nitric oxide concentration in exhaled breath (FeNO), a noninvasive indicator of airway inflammation, remains controversial as a tool to assess asthma control. Guidelines currently limit asthma control assessment to symptom and spirometry based appraisals such as the Asthma Control Questionnaire-7 (ACQ-7). We aimed at determining whether adding FeNO to ACQ-7 improves current asthma clinical control assessment, through enhanced detection of not well controlled asthma.
View Article and Find Full Text PDF